Hormonal
Dietary fiber and probiotic-induced short-chain fatty acids (SCFAs) reduce blood pressure and improve vascular health through G-protein coupled receptor signaling and histone deacetylase inhibition.
Increase your intake of dietary fiber and consider probiotics to boost short-chain fatty acid production. This metabolic shift activates specific receptors (GPR41/43) and enzymes that help lower blood pressure and improve vascular function. Focus on non-starch polysaccharides and low-digestible saccharides found in whole plant foods.
Results from two independent meta-analyses of randomized-controlled trials suggested that increased SCFA induced by probiotics or dietary fiber intake was associated with a reduction in blood pressure in patients with hypertension... Intra-venous administration of propionate in vivo in mice lowered blood pressure... Repeated intraperitoneal injections of butyrate in mice chronically infused with angiotensin II were able to significantly reduce blood pressure.
Why this rating
Supported by multiple meta-analyses of RCTs in humans and consistent animal models, though specific human dosing protocols vary.
Source
Implication of gut microbiota metabolites in cardiovascular and metabolic diseases
François Brial et al. · Cellular and Molecular Life Sciences · 2018
DOI 10.1007/s00018-018-2901-1
More from this paper
- Elevated plasma levels of Trimethylamine-N-oxide (TMAO) are associated with increased risk of cardiovascular disease, thrombosis, and atherosclerosis, primarily through platelet hyper-reactivity and macrophage scavenger receptor stimulation.Good
- Elevated plasma Branched-Chain Amino Acids (BCAAs) are associated with insulin resistance and type 2 diabetes risk, though genetic evidence suggests insulin resistance may drive BCAA levels rather than the reverse.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →